Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics

Journal of Cellular Physiology

Volumn 212, Issue 3, 2007, Pages 710-716

  Rosetti, Marco ^a   Zoli, Wainer ^b   Tesei, Anna ^b   Ulivi, Paola ^a   Fabbri, Francesco ^a   Vannini, Ivan ^a   Brigliadori, Giovanni ^a   Granato, Anna Maria ^a   Amadori, Dino ^b   Silvestrini, Rosella ^b  

^a ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CASPASE; DOCETAXEL; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATINUM DERIVATIVE; PROTEIN P21;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MUTATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TIME FACTORS;

EID: 34547962116     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21067     Document Type: Article

References (45)

1. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. 2004. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10:1976-1983.
2. Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ. 2003. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195-1205.
3. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, Gonzalez JL, Almenar D, Blasco A, Rosell R, Carrato A, Vinolas N, Batista N, Giron CG, Galan A, Lopez M, Blanco R, Provencio M, Diz P, Felip E. Spanish Lung Cancer Group. 2006. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial. Ann Oncol 17:467-472.
4. Chang GC, Hsu SL, Tsai JR, Liang FP, Lin SY, Sheu GT, Chen CY. 2004. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 68:1453-1464.
5. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:25-27.
6. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063.
7. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G. 2002. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98:463-169.
8. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. 2003. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 8:303-306.
9. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WDJr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. 2004. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10:1212-1218.
10. de Marinis F, De Santis S, De Petris L. 2006. Second-line treatment options in non-small cell lung cancer: A comparison of cytotoxic agents and targeted therapies. Semin Oncol 33:S17-S24
11. Dent P, Grant S. 2001. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: Potential role in promoting cytotoxic drug action. Clin Cancer Res 7:775-783.
12. Di Gennaro E, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M, Abbruzzese A, Avallone A, Comella P, Caponigro F, Pepe S, Budillon A. 2003. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J Cell Physiol 195:139-150.
13. Di Maio M, Gridelli C, Normanno N, Perrone F, Ciardiello F. 2005. Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Cell Physiol 205:355-363.
14. Fanucchi M, Khuri FR. 2006. Taxanes in the treatment of non-small cell lung cancer. Treat Respir Med 5:181-191.
15. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. 2000. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens The TAX 320 Non-Small Cell Lung Cancer study group. J Clin Oncol 18:2354-2362.
16. Gasperi-Campani A, Roncuzzi L, Ricotti L, Lenzi L, Gruppioni R, Sensi A, Zini N, Zoli W, Amadori D. 1998. Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines. Cancer Genet Cytogenet 107:11-20.
17. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 5:785-794.
18. Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M. 2005. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65:4253-4260.
19. Hiyama H, Iavarone A, Reeves SA. 1998. Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene 16:1513-1523.
20. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. 2003. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316-2326.
21. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. 2005. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 65:10524-10535.
22. Kris MG. 1998. What does chemotherapy have to offer patients with advanced-stage non-small cell lung cancer? Semin Oncol 25:S1-S4.
23. Kris MG. 2005. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. Oncologist 10:S23-S29.
24. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
25. Manegold C, Gatzemeier U, Buchholz E, Smith RP, Fandi A. 2005. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 6:343-349.
26. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. 2000. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 60:5390-5394.
27. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F. 2005. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16:61-68.
28. Non-Small Cell Lung Cancer Collaborative Group. 1995. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909.
29. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. 2004. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3:465-172.
30. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
31. Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, Calistri D. 2001. Multiple detection of genetic alteration in tumors and stool. Clin Cancer Res 7:590-593.
32. Rosetti M, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Granato AM, Amadori D, Zoli W. 2005. Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biol Ther 4:1089-1095.
33. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Bianco AR, Boni C, Marangolo M, Failla G, Adamo V, Altavilla G, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M. on behalf of the Italian Lung Cancer Project, Orbassano (Torino), Italy. 2001. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 20:1227 (Abstract).
34. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Eastern Cooperative Oncology Group. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Eng J Med 346:92-98.
35. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M. 2005. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389-8395.
36. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. 2000. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103.
37. Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, Katakura H, Wada H. 2002. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 20:3865-3871.
38. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. 2000. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892.
39. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
40. Taja-Chayeb L, Candelaria M, Brom R, Trejo-Becerril C, Meza F, Duenas-Gonzalez A. 2005. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. Lung Cancer 50:259-263.
41. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GRJr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. 2006. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7:326-331.
42. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, Tanaka S, Suga T, Saito R, Ishizuka T, Dobashi K, Minna JD, Nakajima T, Mori M. 2005. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11:6816-6822.
43. Tsavaris N, Kosmas C, Skopelitis E, Gennatas K, Zorbala A, Papas P, Gouveris P, Antypas G, Rokana S, Tzelepis G. 2005. A phase II study of the docetaxel-carboplatin chemotherapy regimen in advanced non-small-cell lung cancer. Lung 183:405-416.
44. Wang LG, Liu XM, Kreis W, Budman D. 1999. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 44:355-361.
45. Woodburn JR. 1999. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250.